Results 81 to 90 of about 23,836 (161)

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan, Zhexin Zhang, Jiaxin Wang, Roland Andersson, Daniel Ansari, Jinfei Chen   +5 more
wiley   +1 more source

Bioactive peptides in cancer and inflammation: Mechanisms, model systems and clinical translation

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Bioactive peptides (BAPs) derived from host, marine, insect, plant and synthetic sources share cationic, amphipathic structures adopting α‐helical, β‐sheet or cyclic conformations. These features underlie anti‐cancer effects, including membrane disruption, apoptosis and cell‐cycle arrest, anti‐metastatic activity, reduced invasion and migration, and ...
Najwa Doha, Richa Gill, Sergio Crovella, Haissam Abou‐Saleh, Sahar Isa Da'as   +4 more
wiley   +1 more source

ATF6‐mediated GTPase RHOQ promotes liver cancer progression via enhancing aerobic glycolysis through PAK1 phosphorylation

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
• RHOQ is a novel direct transcriptional target of ATF6 in HCC. • High RHOQ expression is associated with unfavourable clinicopathological features and poorer PFS. • RHOQ drives HCC progression via PAK1 activation and aerobic glycolysis. • Combining the PAK1‐specific inhibitor IPA‐3 with GPC3‐targeted CAR T‐cell therapy produces a potent synergistic ...
Yuange Zheng, Wei Li, Yuxin Guo, Xilin Zhu, Ying Liu, Xiaopan Wu   +5 more
wiley   +1 more source

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

Advancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translation

MedComm, Volume 7, Issue 10, October 2026.
In vivo CAR‐T cell generation directly engineers endogenous T cells using pre‐manufactured gene delivery vectors that target T cells and deliver CAR‐encoding genetic material. The resulting CAR‐T cells expand in vivo and mediate antigen‐specific cytotoxicity.
Zhenxin Bai, Ming Yi, Shengtao Hu, Dixuan Xue, Luxin Wei, Lifeng Zhang, Zhijun Dai   +6 more
wiley   +1 more source

uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor

Aging Cell, Volume 25, Issue 10, October 2026.
GFD‐CD3, a uPAR‐targeting T‐cell engager, effectively cleared senescent cells and mitigated age‐related pathologies with a favorable safety profile under transaminase‐guided monitoring. ABSTRACT Senolytic CAR‐T cells targeting uPAR induce dose‐dependent toxicities.
Jian Deng, Xiaozhu Zeng, Jing Guo, Lihong Li, Shirui Zou, Nan Liu, Shuai He, Lanzhen Yan, Qiong Wang, Yongjie Zhu, Ben Wang, Dong Yang, Longbao Lv, Xudong Zhao   +13 more
wiley   +1 more source

Biomimetic nanoparticles coated with ScFv-modified macrophage membranes for siRNA delivery to relieve brain metastases of lung cancer

BMC Biotechnology
Background In China, lung cancer stands as the leading cause of cancer-related deaths, often resulting in brain metastases (BM) that severely compromise patients’ quality of life and reduce survival outcomes. The delivery of drugs to the brain is further
Yuan Lu, Yan Qiao, Ting Wu, Yijing Zhang, JiaXin Shi, Jun Jiang   +5 more
doaj   +1 more source